O-RAN Alliance Releases First Software Code
3.12.2019 14:37:00 EET | Business Wire | Press release
Today, the O-RAN Alliance, working with the Linux Foundation, announced the O-RAN Software Community's first software code release, “Amber”.
The goal of the O-RAN Software Community is to advance opening the Radio Access Network (RAN) with a focus on the open interfaces, followed by implementations that leverage new capabilities enabled by the O-RAN specifications.
The Amber release includes initial contributions across 11 software projects. Key highlights include:
- The demonstration of the Operation and Maintenance O1 interface, including multi-vendor radio support.
- The initial release of the O-RAN unique Near Real-Time RAN Intelligent Controller. The Near-RT RIC aims at increasing network performance. It utilizes closed loop (~10ms) measurements to optimize load, energy consumption or other parameters across multiple radios. The O-RAN solution benefits from open access to local RAN data and leverages the O-RAN open architecture, including the E2 and O1 interfaces.
- 3 initial Near-RT RIC microservices (X-APPs) on network admission control, network KPI monitoring and KPI measurement.
- An initial RAN protocol stack from 4G LTE with extendable framework towards 5G standalone mode that leverages the multi-vendor O-RAN architecture with the open fronthaul interface and the F1 interface.
The Amber Release is available at the O-RAN Software Community wiki pages.
The O-RAN Software Community plans to continue rapid development of O-RAN compliant software, following the Linux Foundation 6 months release cycle.
“The first release of the O-RAN Software Community exemplifies the progress we've made as an industry, and AT&T is proud to be a member and active contributor of this effort," said Andre Fuetsch, Chairman of the O-RAN Alliance, Executive Vice President and Chief Technology Officer of AT&T. “Together, we’re driving forward open networking, software and virtualization in global wireless networks, which is critical as we shift to a 5G world.”
"We are really pleased to deliver the first release of the O-RAN Software Community with key elements in both repositories in such a short period of time," said Chih-Lin I, Co-chair of O-RAN Technical Steering Committee (TSC), Chief Scientist of China Mobile. "The Amber Release provides a good framework for the non-realtime RIC and the near-realtime RIC under Apache 2.0, as well as the O-CU and the O-DU under the FRAND-based O-RAN Software License. It demonstrates the value of close alignment between the specification work and the corresponding open source software development.”
“The TOC is proud of all the contributors who have worked hard to bring together the first release of software for an open and intelligent RAN in such a short time,” said John Murray, co-chair of the O-RAN Software Community Technical Oversight Committee and AVP advanced technologies, AT&T. “It is an exciting and evolving domain that is at the front of technology changing our world. The first release is the start of the project and we expect the contributions and functionality to continue as we grow the community of contributors and deliver additional releases in the future.”
“At Nokia we are strong proponents of O-RAN’s core principles of intelligence and openness and believe it will motivate collaboration and drive innovative new services in the industry,” said Michael Clever, Head of Cloud RAN Solutions at Nokia. “We are pleased to be contributing to the Near-RT RIC software in the O-RAN Amber Release. This and future contributions will help prove out the Near-RT RIC and pave the way for wider adoption.”
“Radisys is a champion of O-RAN Alliance and our open strategy has been a guiding beacon for us to help foster the open RAN ecosystem,” said Neeraj Patel, SVP and GM, MobilityEngine Business Unit, Radisys. “We have been working with the O-RAN Alliance and Linux Foundation to bring an open O-DU and O-CU protocol stack as part of the Amber Release. Radisys will continue to play an active role both as an enabler and integrator to fast track the operationalization and commercialization of a multi-vendor ecosystem for 5G RAN.”
“We are pleased to see the O-RAN Software Community issue its first software release, especially in such a short time since forming the project,” said Arpit Joshipura, general manager, Networking, Edge and IoT, the Linux Foundation. “The speed in which this collaboration came together represents a strong commitment across the open source networking ecosystem towards the harmonization of both open source and open standards, as well as cross-stack integration.”
About O-RAN Alliance and the O-RAN Software Community
The O-RAN Alliance is a world-wide, carrier-led effort with more than 130 member operators, vendors, and research & academic institutions operating in the Radio Access Network industry. Its mission is to drive new levels of openness in the radio access network of next generation wireless systems. Future RANs will be built on a foundation of virtualized network elements, white-box hardware and standardized interoperable interfaces that fully embrace O-RAN’s core principles of intelligence and openness.
For more information please visit www.o-ran.org.
The O-RAN Software Community was jointly created by the O-RAN Alliance and the Linux Foundation in April 2019. Its mission is to provide a software solution to support the implementation of an open and intelligent Radio Access Network (RAN), compliant with the O-RAN Alliance specifications.
For more information please visit www.o-ran-sc.org.
About the Linux Foundation
Founded in 2000, the Linux Foundation is supported by more than 1,000 members and is the world's leading home for collaboration on open source software, open standards, open data, and open hardware. Linux Foundation's projects are critical to the world's infrastructure including Linux, Kubernetes, Node.js, and more. The Linux Foundation's methodology focuses on leveraging best practices and addressing the needs of contributors, users and solution providers to create sustainable models for open collaboration. For more information please visit us at www.linuxfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005530/en/
Contact information
Zbynek Dalecky
O-RAN Alliance e.V.
pr@o-ran.org
+420 603 400 524
Jill Lovato
The Linux Foundation
jlovato@linuxfoundation.org
+1 503 703 8268
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
